Sana Biotechnology, Inc.

NasdaqGS:SANA Stock Report

Market Cap: US$2.3b

Sana Biotechnology Management

Management criteria checks 4/4

Sana Biotechnology's CEO is Steve Harr, appointed in Sep 2018, has a tenure of 5.67 years. total yearly compensation is $2.67M, comprised of 24.7% salary and 75.3% bonuses, including company stock and options. directly owns 4% of the company’s shares, worth $92.46M. The average tenure of the management team and the board of directors is 3.8 years and 4.8 years respectively.

Key information

Steve Harr

Chief executive officer

US$2.7m

Total compensation

CEO salary percentage24.7%
CEO tenure5.7yrs
CEO ownership4.0%
Management average tenure3.8yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

Sana Biotechnology: Now In Overbought Territory

Mar 17

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Jan 11

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Dec 30
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 14
Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

May 26
Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Dec 19
We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 03
Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sana Biotechnology A Buy For Potential Cancer Therapies

Jun 27

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

May 16
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Sana Biotechnology: Exciting Preclinical Science

Feb 12

Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Oct 13
Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Sana Biotechnology: Hypoimmune Cell Therapies

Jul 01

Sana Biotechnology reports Q1 results

May 05

CEO Compensation Analysis

How has Steve Harr's remuneration changed compared to Sana Biotechnology's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$3mUS$659k

-US$283m

Sep 30 2023n/an/a

-US$276m

Jun 30 2023n/an/a

-US$362m

Mar 31 2023n/an/a

-US$320m

Dec 31 2022US$4mUS$645k

-US$269m

Sep 30 2022n/an/a

-US$300m

Jun 30 2022n/an/a

-US$298m

Mar 31 2022n/an/a

-US$207m

Dec 31 2021US$1mUS$611k

-US$356m

Sep 30 2021n/an/a

-US$358m

Jun 30 2021n/an/a

-US$327m

Mar 31 2021n/an/a

-US$433m

Dec 31 2020US$7mUS$535k

-US$285m

Compensation vs Market: Steve's total compensation ($USD2.67M) is below average for companies of similar size in the US market ($USD5.67M).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.


CEO

Steve Harr (53 yo)

5.7yrs

Tenure

US$2,671,662

Compensation

Dr. Steven D. Harr, also known as Steve, M.D., is President and Chief Executive Officer at Sana Biotechnology, Inc. since September 2018 and also serves as its Director since October 2018. He served as the...


Leadership Team

NamePositionTenureCompensationOwnership
Steven Harr
President5.7yrsUS$2.67m4%
$ 92.5m
Nathan Hardy
Executive VP & CFO5.7yrsUS$1.19mno data
Snehal Patel
Senior VP & Chief Technical Officerless than a yearno datano data
Bernard Cassidy
Executive VP1.7yrsUS$4.26m0.042%
$ 968.6k
Robin Andrulevich
Executive VP & Chief People Officer5.7yrsno datano data
Edward Rebar
Head of Cell Engineeringless than a yearno datano data
Paul Brunetta
Senior VP and Head of Clinical & Translational Scienceno datano datano data
Christian Hordo
Executive VP & Chief Business Officer5.6yrsUS$1.59m0.39%
$ 9.1m
Sonja Schrepfer
Senior VP & Head of Hypoimmune Platform5.3yrsno datano data
Terry Fry
Senior VP & Head of T Cell Therapeutics3.8yrsno datano data
Steven Goldman
Senior VP & Head of CNS Therapy3.6yrsno datano data
Farah Anwar
Head of Development Operations & IDE Leader3.5yrsno datano data

3.8yrs

Average Tenure

55yo

Average Age

Experienced Management: SANA's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Steven Harr
President5.6yrsUS$2.67m4%
$ 92.5m
Robert Taylor Nelsen
Independent Director5.6yrsUS$294.80k0.0063%
$ 144.6k
Mary Wilderotter
Independent Director4yrsUS$314.80k0.0032%
$ 74.2k
Douglas Cole
Independent Director4.1yrsUS$302.30k0%
$ 0
Patrick Yang
Independent Director5.6yrsUS$299.80k0.067%
$ 1.6m
Michelle Seitz
Independent Director3.5yrsUS$314.80k0%
$ 0
Richard Mulligan
Vice Chairman5.5yrsno data1.35%
$ 31.3m
Hans Edgar Bishop
Independent Chairman of the Board5.6yrsUS$354.80k2.61%
$ 60.3m
Joshua Bilenker
Independent Director3.4yrsUS$299.80k0.0090%
$ 208.9k
Alise Reicin
Independent Director3.4yrsUS$302.30k0%
$ 0

4.8yrs

Average Tenure

61.5yo

Average Age

Experienced Board: SANA's board of directors are considered experienced (4.8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.